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ABSTRACT. The purpose of this study is to verify whether acute pre-treatment with alprazolam (ALP), a 
benzodiazepine that inhibits HPA secretion in normal subjects, could better characterize patients with 
subclinical Cushing’s syndrome (SCS) than the 1-mg dexamethasone test (DST).  
In 22 patients with SCS, 10 with overt Cushing’s syndrome (CS), 11 with non-functioning adrenal 
incidentalomas (NF) and 14 normal subjects (NS) we studied the effect of ALP (1 mg, p.o. at 2300 hours) 
on cortisol levels after 1-mg DST. Cortisol levels (mean ± SEM) after DST were lower (P = 0.012) in SCS 
(3.9 ± 0.3 µg/dl) than in overt CS (10.4 ± 1.9 lg/dl), while they were higher (P = 0.0005) than in NF (1.1 ± 
0.1 µg/dl) and NS (1.5 ± 0.1 µg/dl). After ALP pre-treatment, cortisol levels further decreased (P = 0.004) 
in SCS (3.0 ± 0.3 lg/dl), but neither in CS (9.3 ± 1.3 lg/dl) nor in NF (1.3 ± 0.1 µg/dl) and in NS (1.3 ± 0.1 
µg/dl). In SCS, cortisol levels after ALP +1-mg DST persisted lower (P = 0.0005) than those in CS, but 
higher (P = 0.0005) than those in NF and NS. Considering individual cases, ALP pre-treatment reduced 
cortisol levels <3 and a1.8 lg/dl in 50 and 23 % of SCS patients, respectively. ALP amplifies the cortisol 
inhibition exerted by 1-mg DST in patients with SCS but not in those with CS. The clinical usefulness of 
ALP to increase the sensitivity of 1-mg DST to identify true autonomous cortisol release in patients with 
adrenal incidentalomas as well as to predict different clinical outcomes remains to be clarified. 
Introduction 
Subclinical Cushing’s syndrome (SCS) is defined as a status of altered hypothalamic–pituitary–adrenal 
(HPA) axis secretion characterized by an autonomous and unreg- ulated cortisol secretion, not fully 
restrained by pituitary feedback, in the absence of the classical signs or symptoms of overt cortisol excess  
[1–5]. 
Subclinical Cushing’s syndrome was initially reported around 30 years ago in patients studied for 
incidentally discovered adrenal masses [6, 7], the so called adrenal incidentalomas, that have become a 
common finding in clinical practice. In fact, the widespread use of abdominal ultrasonography, computed 
tomography (CT) and magnetic resonance imaging (MRI), have led to an increase in the detection of 
adrenal incidentalomas in recent years, rang- ing between 1 and 8.7 % [8]; the interest of SCS in this 
population is due to its high prevalence, ranging between 5 and 30 % of different series [4,   5]. 
Among the various tests used for the diagnosis of SCS, the 1-mg dexamethasone test (DST) is considered 
the most valuable test to screen for SCS, either alone or in combi- nation  with  other parameters [4, 5]. 
Dexamethasone  is   a synthetic glucocorticoid (GC) with selectivity for gluco- corticoid receptor (GR), that 
preferentially activates pitui- taric GRs and has been extensively employed to assess the integrity of the 
HPA-axis feed-back [9, 10]. It is used to evaluate the status of the HPA axis in adrenal inciden- talomas, 
applying concepts derived by screening of overt cortisol excess [11]. The 1-mg DST cortisol cut-off is still 
a matter of debate, being the cut-off of 1.8 lg/dl (50 nmol/l) considered as having the highest sensitivity [4, 
5, 8, 12–14], while the cut-off of 3.0 lg/dl (83 nmol/l) has been demonstrated by some Authors as having 
the best com- promise  between  sensitivity  and  specificity  [4].  On  the other hand, the Endocrine Society 
Clinical Guidelines for the diagnosis of Cushing’s syndrome recommended the cut-off for of 1.8 lg/dl for 
the initial hormonal evaluation of patients with suspected overt cortisol excess   [11]. 
Alprazolam (ALP), a benzodiazepine (BDZ) activating c-amino butyric acid (GABA)-ergic receptors, 
exhibits a clear inhibitory effect on HPA axis secretion [15, 16] through an inhibitory influence on CRH- 
and/or AVP secreting neurons [15, 16]. In fact, in normal subjects ALP inhibits the ACTH and cortisol 
responses to several stimulations, such as vasopressin, metabolic and mental stress, naloxone and synthetic 
GH-secretagogues [17–22]. Moreover, although ALP failed to modify CRH-induced ACTH secretion from 
rat pituitary [15] and it does not inhibit the ACTH and cor- tisol responses to exogenous CRH in humans 
[19, 23], the existence of GABA/BDZ receptors in the pituitary gland suggested a direct modulatory role of 
GABA and/or BDZ on corticotroph secretion induced by ACTH secretagogues other than CRH [15, 16]. 
Moreover, ALP did show a marked inhibitory effect even on ACTH rise induced by metyrapone or insulin-
induced hypoglycemia, the most potent stimula- tions of corticotroph secretion [24, 25], as well as on HPA 
response to the blockade of mineralocorticoid receptors [26], clearly indicating a primary role of GABA-
ergic pathways in the modulation of HPA activity in physiological conditions. There is evidence that ALP 
still inhibits, though with less potency, HPA response to different ACTH secreta- gogues in clinical 
conditions characterized by functional HPA hyperactivity, such as obesity [22], while it does not modify 
ACTH and cortisol responses in patients with overt Cushing’s syndrome [22, 27], suggesting that the 
inhibitory influence of GABA/BDZ is lost in patients with organic hypercortisolism. 
Interestingly, ALP has been demonstrated to also bind to the peripheral benzodiazepine receptors (PBR), 
structurally and functionally different to GABA receptors, that have been shown to play a critical role in 
steroidogenetic pro- cesses leading to the synthesis of both neurosteroids and steroid hormones in adrenal 
gland; moreover, they also exert a modulator influence on the activity of the anterior pituitary gland [28, 
29]. 
 Based on these premises, the aim of the present study was to verify the effect of acute ALP pre-treatment 
on cortisol response to 1-mg DST in patients with SCS, comparing them with patient with overt CS, non-
functioning adrenal adenomas and normal subjects. 
 
Subjects and methods 
Thirty-three  consecutive  patients  (21  F  and  12 M;   age 57.4 ± 1.2 years) with adrenal masses 
incidentally dis- covered by abdominal CT or MRI, 10 patients with overt Cushing’s syndrome (CS, 9 F and 
1 M; age 53.0 ± 3.2 years) due to either cortisol-secreting adenomas (n = 5) or ACTH-secreting pituitary 
adenomas (n = 5), and 14 normal subjects (NS, 7 F and 7 M; age 54.6 ± 3.4 years) were studied. Patients 
with adrenal incidentalomas were further subdivided into two groups: 1) with SCS (n = 22; 14 F and 8 M; 
age 58.1 ± 1.2 years); 2) with non-functioning adrenal adenomas (NF; n = 11; 7 F and 4 M; age 55.9 ± 
2.9 years). The diagnosis of SCS was based on a post 1-mg-DST cortisol level [1.8 µg/dl (50 nmol/l) 
combined with an abnormal result in at least one of the following tests: (1) post-low dose dexamethasone 
suppression test (LDDST) cortisol levels [1.8 µg/dl (50 nmol/l); (2) absence of cortisol rhythm [midnight 
serum cortisol [7.5 µg/dl (220 nmol/)]; (3) low ACTH levels [<5 pg/ml (1.1 pmol/l)]; (4) high UFC  [[100 
µg/24 h  (275 mmol/ 24 h)], in the absence of clinical signs or symptoms of cortisol excess. 
The diagnosis of CS as well as the differentiation between ACTH-dependent and ACTH-independent was 
based on International Guidelines [11]. The patient with ACTH- dependent CS underwent pituitary MRI 
that detected a micro-adenoma in all cases. 
All the subjects gave their informed consent to partici- pate in the study, which had been approved by the 
local ethical committee, in agreement with the Declaration of Helsinki. 
All the subjects underwent 1-mg DST (1 mg dexameth asone administered orally at 2300 hours, and blood 
sample drawing on the following morning at 0800 hours for deter mination of serum cortisol concentration) 
and  alprazolam (ALP, 1 mg administered orally at 2200 hours) + 1-mg DST. 
Serum cortisol levels (1  µg/dl 9 27.7 = 1 nmol/l; nor- mality, range 6.2–19.4 µg/dl) were measured in 
duplicate by competitive electrochemiluminescence immunoassay on cobas e601 instrument (Roche 
Diagnostics     GmbH, Sandhofer Strasse 116, D-68305 Mannheim, Germany), with the sensitivity of the 
assay that was 0.01 µg/dl and the intra- and inter-assay coefficients of variations that ranged from 3.0 to 5.7 
% and from 2.4 to 6.2 %, respectively. 
 Plasma ACTH levels (1 pg/ml 9 0.22 = 1 pmol/l; nor- mality, range 5–46 pg/ml) were measured in 
duplicate by Immulite 2000 (Siemens Healthcare Diagnostics Inc., Llanberis, Gwynedd LL55 4EL, 
UnitedKingdom), with the sensitivity of the assay that was 5 pg/ml, and the inter-and intra-assay 
coefficients of variation that ranged from 6.1 to 10 % and from 6.7 to 9.5 %, respectively. 
Urinary  free  cortisol  levels  (UFC,  1 µg/24 h 9 2.75 =1 nmol/d; normality, range 10–90 lg/24 h) were 
measured in duplicate by micro particle-based chemiluminescence auto- mated on Architect i2000 analyzer 
without extraction (Abbott Diagnostics, Abbott Park, IL, USA), with the sensitivity of the assay  that  was  
1.0 µg/24 h  and  the  inter-and  intra-assay coefficients of variation that ranged from 4.2 to 8.9 % and from 
4.7 to 11.5 %, respectively. 
 
Statistical analysis 
The data were expressed as mean ± SEM. 
All statistical analyses were performed using Statistical Package for the Social Science (SPSS 19.0 for 
Windows: SPSS Inc., 1989–2005, Chicago IL, USA) [30]. A value of P < 0.05 was considered to be 
significant. 
The statistical analysis was carried out by using non- parametric Mann–Whitney test for the comparison 
between groups and the Wilcoxon test for the comparison between two testing sessions in the same group of   
patients. 
Correlations between cortisol levels after ALP + 1-mg DST and midnight serum cortisol, ACTH levels and 
UFC in SCS patients were carried out by using the Pearson correlation coefficient and multiple linear 
regression anal- ysis among the above variables was then   performed. 
 
 
Results 
Cortisol levels (mean ± SEM) after 1-mg DST were lower (P = 0.012) in SCS (3.9 ± 0.3 µlg/dl) than in 
overt CS (10.4 ± 1.9 µg/dl), while they were higher (P = 0.0005) than those in NF (1.1 ± 0.1 lg/dl) and NS 
(1.5 ± 0.1 µg/dl). Considering individual cases, 1-mg DST inhibited cortisol levels <3 µg/dl in 8 SCS 
patients (36 %, cases 1, 3, 5, 12, 13, 14, 15, 20) (Table 1; Figs. 1,   2). 
After ALP pre-treatment cortisol levels further decreased (P = 0.04) in SCS (3.0 ± 0.3 µg/dl), but neither in 
CS (9.3 ± 1.3 µg/dl) nor in NF (1.3 ± 0.1 µg/dl) and in NS (1.3 ± 0.1 µg/dl). In SCS, cortisol levels after 
ALP ? 1-mg DST persisted lower (P = 0.0005) than those in CS, but higher (P = 0.0005) than those in NF 
and NS (Table 1; Fig. 1). 
Considering individual cases, cortisol levels after ALP + 1-mg DST were [3 µg/dl in all CS patients, while 
ALP did not further inhibit post DST cortisol levels in none of NF and NS subjects. On the contrary, ALP 
pre-treatment further reduced cortisol levels <3 lg/dl in 11 SCS patients (50 %,  cases  4, 5, 7, 8, 9,  10, 12,  
15, 17,  18, 20)   and <1.8 lg/dl in 5 SCS patients (23 %, cases 4, 7, 8, 15, 18) (Table 1; Fig. 2). 
In SCS a significant positive correlation between corti- sol levels after ALP + 1-mg DST and midnight 
serum cortisol levels was found (r = 0.44, P = 0.04), while no significant correlation between cortisol  levels  
after  ALP + 1-mg DST and ACTH levels or UFC was found. 
At the multiple regression analysis, in SCS midnight serum cortisol was the best predictor of cortisol levels 
after ALP + 1-mg DST (b = 0.48, P = 0.02). 
Discussion 
The results of this study show that ALP, a benzodiazepine activating GABA-ergic receptors, amplified the 
cortisol inhibition exerted by 1-mg DST in patients with subclinical Cushing’s syndrome, while it did not 
modify the cortisol levels in those with overt Cushing’s  syndrome. 
The inhibitory effect of GABA/BDZ receptor activation on HPA activity has previously been demonstrated 
in both animals and humans. Among the various BDZ commonly used in clinical practice, ALP showed so 
far the most remarkable inhibitory effect on the HPA axis, being evi- dent on both basal and stimulated-
ACTH and cortisol secretion, at least in physiological conditions [15, 16]. In fact, ALP has been shown to 
significantly reduce basal corticotroph and adrenal secretion either in animals [15] or in humans [16, 24, 
31]. On the other hand, ALP has been shown to significantly blunt the HPA response to several 
stimulations; in particular, while in animals it has been demonstrated to inhibit the corticotroph response to 
insulin- induced hypoglicemia and serotonin-stimulated CRH secre tion [15], in humans it significantly 
decreases the ACTH/ cortisol response to metyrapone and insulin-induced hypo- glycemia, the most potent 
stimulations of corticotroph secretion [24, 25]. 
About mechanisms of action, either CRH- or AVP- mediated central actions has been hypothesized. In 
particular, ALP has been demonstrated to act at hypothalamic level, via inhibition of CRH release, being 
able to inhibit the ACTH and cortisol response to CRH-mediated stimuli, to AVP but not to exogenous 
CRH [17–20, 24]. On the other hand, other studies indicate that ALP could act via AVP-mediated 
mechanisms [27], although some authors did not find any significant effect of ALP on AVP release in 
humans [23]. It has also been proposed that ALP may influence HPA axis by acting at supra-hypothalamic 
level, as it has been shown to counteract the stimulatory effects of  substances  which  reduce  the  GC-
mediated    negative feed-back by acting at supra-hypothalamic level [24, 26]. Moreover, although BDZ 
failed to modify CRH-induced ACTH secretion from rat pituitary [15], the existence of GABA/BDZ 
receptors in the pituitary gland suggested a direct modulator role of GABA and/or BDZ on cortico- troph 
secretion induced by ACTH secretagogues other than CRH. 
Our present results showing that ALP partially amplifies the cortisol inhibition exerted by 1 mg DST in  
patients with subclinical hypercortisolism suggest that GABA/BDZ system still modulates cortisol secretion 
in these patients, indicating that this condition is not characterized by a complete ACTH independence of 
cortisol secretion. Con versely, in patients with overt Cushing’s syndrome, both pituitary ACTH-secreting 
and cortisol-secreting adrenal adenomas, ALP did not modify cortisol response to 1 mg DST, confirming 
previous data in literature demonstrating that these patients are not sensitive to the inhibitory effects of 
GABA/BZD [22, 27]. 
 In this context, we hypothesized that ALP could be more effective in subclinical Cushing’s syndrome 
patients with non- suppressed ACTH levels, suggesting in these patients a more clear ACTH dependence of 
cortisol secretion, possibly reflecting a somewhat functional HPA hyperactivation and not a true 
autonomous cortisol secretion. Unfortunately, we did not find a significant correlation between  basal  
ACTH  levels  and  suppression  of cortisol after ALP + DST. This may simply reflect the   small number of 
subjects enrolled in our study, although the hypothesis that in these patients the cortisol inhibiting effect of 
GABA/BZD does occur independently of ACTH levels cannot be  excluded. 
Our present results showing a positive correlation between cortisol levels after ALP + 1-mg DST and mid- 
night serum cortisol levels in SCS are in agreement with previous reports showing an individual set point of 
sensitivity to the mechanisms controlling HPA activity [32], again suggesting a somewhat functional HPA 
hyperactivation and  not a true autonomous cortisol secretion in these patients; moreover, similarly to what 
reported in patients with overt Cushing’s syndrome [11], both these hormonal alterations may be the earliest 
and most sensitive markers of endoge- nous glucocorticoid excess in these patients. 
Finally, a peripheral effect of ALP on adrenal gland can be hypothesized. In fact, ALP has been 
demonstrated to act, in the adrenal gland, through PBR, structurally and functionally different to GABA 
receptors, that play a critical role in steroidogenetic processes involved in the synthesis of both 
neurosteroids and peripheral steroid hormones [28, 29]. Although PBR activation by BDZ has been 
demonstrated to stimulate steroidogenesis in the adrenal gland by some authors, other studies showed an 
inhibitory effect of BDZ on ACTH-induced steroidogenesis in ani- mals [28, 29, 33]. The inhibitory effect 
on adrenal secretion induced by the activation of PBR system could explain the ALP effect on cortisol 
response to DST in our subclinical hypercortisolemic patients, in agreement with previous  data showing 
that ALP significantly blunts the adrenal response to low ACTH doses in humans [23]. Conversely, the 
absence of modulation by ALP on cortisol secretion in patients with overt Cushing’s syndrome would 
suggest that PBR system is unable to overcome the strong stimulatory effect induced by either autonomous 
adrenal adenoma or exaggerated ACTH stimulation on cortisol  release. 
 
 Although the clinical usefulness of ALP to increase the sensitivity of 1-mg DST in patients with adrenal 
inciden- talomas remains to be clarified, it’s noteworthy that with the cortisol cut-off of 1.8 µg/dl (50 
nmol/l), about 23 % of patients classified as affected by SCS using 1-mg DST would be considered normal 
after ALP pre-treatment. Moreover, by using the cutoff of 3.0 lg/dl (83 nmol/l), that represents the best 
compromise between sensitivity and specificity accordingly to the opinion of some expert [4], 50 % of 
patients classified as affected by SCS by using 1-mg DST would be considered normal after ALP pre- 
treatment. 
Our choice of screening for SCS with a lower cut-off than those recommended for adrenal incidentalomas 
by international guidelines [8, 12, 14] could have led us to a decrease in specificity and, therefore, to more 
false diag- nosis of SCS, but it was needed for the comparison with CS patients, accordingly to The 
Endocrine Society Clinical Guidelines [11]. On the other hand, this was the cut-off recommended by the 
French Society of Endocrinology in patients with adrenal incidentalomas  [13]. 
  
 
  
Recognizing the limitation of any single test of the HPA axis activity, ALP ? 1-mg DST might become a 
new tool for the diagnosis of SCS in patients with adrenal inciden- talomas with not concordant results 
provided that patients with suppression of cortisol levels after ALP ? 1 mg DST below \1.8 lg/dl show a 
different progression of the dis- ease, in term of hormonal, clinical and morphological parameters during a 
long-term follow up compared with the non-suppressing patients. On the other hand, the doubt remains as 
to whether the patients defined as SCS are really hypercortisolemic and whether the ALP ? 1-mg DST is 
really capable of distinguishing SCS from NF   amongst 
patients with adrenal  incidentaloma. 
In conclusion, this study shows that ALP amplifies the cortisol inhibition exerted by 1-mg DST in patients 
with subclinical hypercortisolism but not in those with overt hypercortisolism. A not complete ACTH 
independence of cortisol secretion and/or a peripheral adrenal inhibiting GABA/BZD effect is suggested in 
subclinical Cushing’s syndrome patients. The clinical usefulness of ALP to increase the sensitivity of 1-mg 
DST for the diagnosis of subclinical Cushing’s syndrome in patients with adrenal incidentalomas as well as 
to predict different clinical out- comes remains to be  clarified. 
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Table 1      Anthropometric, clinical and hormonal data of patients with subclinical Cushing’s syndrome 
 
Case 
(n) 
Sex Age 
(years) 
Adrenal 
imaging 
ACTH 
(pg/ml) 
UFC (lg/ 
24 h) 
Cortisol 
midnight (lg/dl) 
Cortisol LDDST 
(lg/dl) 
Cortisol 1-mg 
DST (lg/dl) 
Cortisol ALP ? 1-mg 
DST (lg/dl) 
1 F 63 L, 30 mm 10 66 8.7 3.5 2.8 3.3 
2 F 62 R, 40 mm 15 72 14.6 9.6 5.6 6.0 
3 F 59 R, 23 mm 5 23 2.6 3.1 2.3 3.8 
4 F 55 R, 30 mm 11 32 5.5 3.6 4.2 1.7 
5 F 57 L, 30 mm 18 136 6.0 4.8 2.6 2.7 
6 F 51 R, 28 mm 5 57 8.0 3.1 3.1 4.2 
7 F 59 R, 12 mm 19 33 6.0 2.6 4.8 1.5 
8 M 63 R, 25 mm 7 63 4.2 3.3 4.4 1.7 
9 M 64 R, 30 mm 9 34 5.1 5.4 3.8 2.3 
10 F 58 L, 29 mm 9 30 5.0 2.4 3.4 2.6 
11 M 59 R, 25 mm 19 36 3.3 6.3 7.0 3.4 
12 F 61 L, 12 mm 16 38 7.0 2.7 2.4 2.7 
13 M 59 R, 15 mm 11 30 4.3 3.2 2.8 4.5 
14 M 59 R, 15 mm 12 30 4.3 3.2 2.8 3.6 
15 F 67 R, 12 mm 11 79 4.8 3.6 2.9 1.7 
16 F 58 R, 40 mm 13 35 3.6 5.0 3.8 5.0 
17 M 57 R, 28 mm 10 54 4.2 3.1 4.6 2.7 
18 M 53 L, 30 mm 7 91 3.1 4.5 5.3 1.7 
19 F 42 R, 24 mm 18 37 6.3 2.7 6.0 5.1 
20 F 49 L, 10 mm 15 45 3.7 3.6 2.5 2.8 
21 M 67 R, 36 mm 18 22 5.7 4.0 4.4 4.0 
22 F 56 L, 30 mm 19 128 4.7 4.2 4.5 3.1 
Mean  58.1  14.1 53.3 5.5 4.0 3.9 3.0 
SEM  1.2  1.5 3.7 0.5 0.3 0.3 0.3 
R, right adrenal adenoma, L, left adrenal adenoma, ACTH (pg/ml; 1 pg/ml 9 0.22 = 1 pmol/l); UFC (lg/24 h; 1 lg/24 h 9 2.75 = 1 
nmol/d); cortisol (lg/dl; 1 lg/dl 9 27.59 = 1 nmol/l); LDDST, low dose dexamethasone suppression test; 1-mg DST , 1 mg 
dexamethasone suppression test; ALP, alprazolam 
 
 
 
 
  
 
 
